Literature DB >> 17291192

Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation.

Samira Benyoucef1, Katharina H Surinya, Dirk Hadaschik, Kenneth Siddle.   

Abstract

The IR (insulin receptor) and IGFR (type I insulin-like growth factor receptor) are found as homodimers, but the respective pro-receptors can also heterodimerize to form insulin-IGF hybrid receptors. There are conflicting data on the ligand affinity of hybrids, and especially on the influence of different IR isoforms. To investigate further the contribution of individual ligand binding epitopes to affinity and specificity in the IR/IGFR family, we generated hybrids incorporating both IR isoforms (A and B) and IR/IGFR domain-swap chimaeras, by ectopic co-expression of receptor constructs in Chinese hamster ovary cells, and studied ligand binding using both radioligand competition and bioluminescence resonance energy transfer assays. We found that IR-A-IGFR and IR-B-IGFR hybrids bound insulin with similar relatively low affinity, which was intermediate between that of homodimeric IR and homodimeric IGFR. However, both IR-A-IGFR and IR-B-IGFR hybrids bound IGF-I and IGF-II with high affinity, at a level comparable with homodimeric IGFR. Incorporation of a significant fraction of either IR-A or IR-B into hybrids resulted in abrogation of insulin- but not IGF-I-stimulated autophosphorylation. We conclude that the sequence of 12 amino acids encoded by exon 11 of the IR gene has little or no effect on ligand binding and activation of IR-IGFR hybrids, and that hybrid receptors bind IGFs but not insulin at physiological concentrations regardless of the IR isoform they contained. To reconstitute high affinity insulin binding within a hybrid receptor, chimaeras in which the IGFR L1 or L2 domains had been replaced by equivalent IR domains were co-expressed with full-length IR-A or IR-B. In the context of an IR-A-IGFR hybrid, replacement of IR residues 325-524 (containing the L2 domain and part of the first fibronectin domain) with the corresponding IGFR sequence increased the affinity for insulin by 20-fold. We conclude that the L2 and/or first fibronectin domains of IR contribute in trans with the L1 domain to create a high affinity insulin-binding site within a dimeric receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17291192      PMCID: PMC1876384          DOI: 10.1042/BJ20061709

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  54 in total

1.  Post-translational changes in tertiary and quaternary structure of the insulin proreceptor. Correlation with acquisition of function.

Authors:  T S Olson; M J Bamberger; M D Lane
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

2.  Functional properties of an isolated alpha beta heterodimeric human placenta insulin-like growth factor 1 receptor complex.

Authors:  S M Feltz; M L Swanson; J A Wemmie; J E Pessin
Journal:  Biochemistry       Date:  1988-05-03       Impact factor: 3.162

3.  Isolation of functional alpha beta heterodimers from the purified human placental alpha 2 beta 2 heterotetrameric insulin receptor complex. A structural basis for insulin binding heterogeneity.

Authors:  L J Sweet; B D Morrison; J E Pessin
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

4.  Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer.

Authors:  Christophe Blanquart; Carmen Gonzalez-Yanes; Tarik Issad
Journal:  Mol Pharmacol       Date:  2006-08-22       Impact factor: 4.436

5.  Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers.

Authors:  C P Moxham; V Duronio; S Jacobs
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

6.  The insulin receptor. Structural basis for high affinity ligand binding.

Authors:  M Böni-Schnetzler; W Scott; S M Waugh; E DiBella; P F Pilch
Journal:  J Biol Chem       Date:  1987-06-15       Impact factor: 5.157

7.  Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose.

Authors:  L Ellis; E Clauser; D O Morgan; M Edery; R A Roth; W J Rutter
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

8.  The structural basis for insulin-like growth factor I receptor high affinity binding.

Authors:  S E Tollefsen; K Thompson
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

9.  Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains.

Authors:  R Lammers; A Gray; J Schlessinger; A Ullrich
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

10.  Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.

Authors:  A Ullrich; A Gray; A W Tam; T Yang-Feng; M Tsubokawa; C Collins; W Henzel; T Le Bon; S Kathuria; E Chen
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

View more
  69 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 2.  Targeting insulin-like growth factor type 1 receptor in cancer therapy.

Authors:  Francesco Atzori; Tiffany A Traina; Maria Teresa Ionta; Bruno Massidda
Journal:  Target Oncol       Date:  2009-10-30       Impact factor: 4.493

3.  Effects of clonal variation on growth, metabolism, and productivity in response to trophic factor stimulation: a study of Chinese hamster ovary cells producing a recombinant monoclonal antibody.

Authors:  Hussain Dahodwala; Mark Nowey; Tatyana Mitina; Susan T Sharfstein
Journal:  Cytotechnology       Date:  2011-08-06       Impact factor: 2.058

4.  In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.

Authors:  Mark R Sommerfeld; Günter Müller; Georg Tschank; Gerhard Seipke; Paul Habermann; Roland Kurrle; Norbert Tennagels
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

5.  Insulin prevents aberrant mitochondrial phenotype in sensory neurons of type 1 diabetic rats.

Authors:  Mohamad-Reza Aghanoori; Darrell R Smith; Subir Roy Chowdhury; Mohammad Golam Sabbir; Nigel A Calcutt; Paul Fernyhough
Journal:  Exp Neurol       Date:  2017-08-10       Impact factor: 5.330

6.  High-affinity insulin binding: insulin interacts with two receptor ligand binding sites.

Authors:  Linda Whittaker; Caili Hao; Wen Fu; Jonathan Whittaker
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

Review 7.  Insulin receptor signaling in the development of neuronal structure and function.

Authors:  Shu-Ling Chiu; Hollis T Cline
Journal:  Neural Dev       Date:  2010-03-15       Impact factor: 3.842

Review 8.  The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.

Authors:  V Kate Gatenby; Helen Imrie; Mark Kearney
Journal:  Pflugers Arch       Date:  2013-01-22       Impact factor: 3.657

9.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Authors:  Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David A Loegering; Kevin L Peterson; Ricardo Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  Harmonic oscillator model of the insulin and IGF1 receptors' allosteric binding and activation.

Authors:  Vladislav V Kiselyov; Soetkin Versteyhe; Lisbeth Gauguin; Pierre De Meyts
Journal:  Mol Syst Biol       Date:  2009-02-17       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.